Inotropic Agents Market Share, Data Forecast To 2024-2033


Posted February 9, 2024 by ravali

Global inotropic agents market size is expected to reach $4.01 Bn by 2028 at a rate of 11.6%, segmented as by type, positive inotropic drugs, negative inotropic drugs, other types
 
The Business Research Company has updated its global market reports with latest data for 2024 and projections up to 2033.

The Inotropic Agents Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions - Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The Inotropic Agents Market:
https://www.thebusinessresearchcompany.com/report/inotropic-agents-global-market-report

According to The Business Research Company’s Inotropic Agents Global Market Report 2024, The inotropic agents market size has grown rapidly in recent years. It will grow from $2.32 billion in 2023 to $2.59 billion in 2024 at a compound annual growth rate (CAGR) of 11.2%. The growth in the historic period can be attributed to education and awareness initiatives, expansion of cardiac treatment options, development of safer agents, improved patient outcomes, regulatory approvals.The inotropic agents market size is expected to see rapid growth in the next few years. It will grow to $4.01 billion in 2028 at a compound annual growth rate (CAGR) of 11.6%.

The rise in the prevalence of cardiovascular diseases is fueling the growth of the inotropic agent market. Cardiovascular diseases (CVDs) affect the heart and vascular system, and inotropic agents are utilized in their treatment to enhance heart contractility, address cardiac shock, and regulate heart rate, ultimately improving blood flow. This increased demand for inotropic agents is driven by the need to address the growing incidence of cardiovascular diseases. For instance, as reported by the Centers for Disease Control and Prevention in October 2022, heart diseases ranked as the leading cause of death in the US, with approximately 697,000 deaths recorded in 2020. Additionally, coronary artery disease affected around 20.1 million adults, with approximately 805,000 people experiencing heart attacks annually. Furthermore, projections from the American College of Cardiology in August 2022 suggested a 33.8% increase in stroke risk by 2060, reaching 15 million cases. Hence, the surge in cardiovascular diseases is significantly driving the inotropic agent market.

Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=10711&type=smp

The inotropic agents market covered in this report is segmented –
1) By Type: Positive Inotropic Drugs, Negative Inotropic Drugs, Other Types
2) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration
3) By Indication: Heart Attack, Heart Failure, Angina, Arrhythmia, Other Indications
4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels
5) By End User: Hospital, Homecare, Specialty Centers, Other End Users

Top Major Players
Pfizer Inc.,
GSK PLC,
Novartis AG,
Mylan N.V.,
Boehringer Ingelheim International GmbH

The inotropic agents market report table of contents includes:
1. Executive Summary
2. Inotropic Agents Market Characteristics
3. Inotropic Agents Market Trends And Strategies
4. Inotropic Agents Market - Macro Economic Scenario
5. Global Inotropic Agents Market Size and Growth
6. Inotropic Agents Market Segmentation
7. Inotropic Agents Market Regional And Country Analysis
.............
33. Key Mergers And Acquisitions In The Inotropic Agents Market
34. Inotropic Agents Market Future Outlook and Potential Analysis
35. Appendix

List Of Tables :
Table 1: Global Historic Market Growth, 2018-2023, $ Billion
Table 2: Global Forecast Market Growth, 2023-2028F, 2033F, $ Billion
Table 3: Global Inotropic Agents Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Table 4: Global Inotropic Agents Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Table 5: Global Inotropic Agents Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
..............
Table 76: Pfizer Inc. Financial Performance
Table 77: GSK plc Financial Performance
Table 78: Novartis AG Financial Performance
Table 79: Mylan N.V. Financial Performance
Table 80: Boehringer Ingelheim International GmbH Financial Performance

Read Related Reports :
https://topprnews.com/healthcare-staffing-market-growth/
https://goodprnews.com/healthcare-staffing-market-size/

Learn About Us:
The Business Research Company is a market intelligence firm that pioneers in market, company, and consumer research. TBRC’s specialist consultants are located globally and are experts in a wide range of industries that include healthcare, manufacturing, financial services, chemicals, and technology. The firm has offices located in the UK, the US, and India, along with a network of proficient researchers in 28 countries.

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
-- END ---
Share Facebook Twitter
Print Friendly and PDF DisclaimerReport Abuse
Contact Email [email protected]
Issued By tbrc
Country United States
Categories Medical
Last Updated February 9, 2024